Lunai Bioworks Management
Management criteria checks 1/4
Lunai Bioworks' CEO is David Weinstein, appointed in Oct 2024, has a tenure of 1.08 years. total yearly compensation is $1.29M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $87.57K. The average tenure of the management team and the board of directors is 1.1 years and 4.3 years respectively.
Key information
David Weinstein
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 23.36% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.1yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Enochian stock climbs on US patent for oncology platform
Oct 17Enochian BioSciences discovers two sets of altered animal data in two of its studies
Jul 01Is Enochian Biosciences (NASDAQ:ENOB) Using Debt Sensibly?
Jun 28
Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Feb 20Enochian Biosciences (NASDAQ:ENOB) Has Debt But No Earnings; Should You Worry?
Oct 30Enochian Biosciences: A Follow Through For An HIV Cure
Jun 26Do Insiders Own Lots Of Shares In Enochian Biosciences, Inc. (NASDAQ:ENOB)?
Feb 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | US$1m | US$302k | -US$178m |
Compensation vs Market: David's total compensation ($USD1.29M) is above average for companies of similar size in the US market ($USD596.13K).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
CEO
David Weinstein (65 yo)
Mr. David H. Weinstein, also known as David, is CEO & Director of Lunai Bioworks Inc. (formerly known as Renovaro Inc.) from October 14, 2024. He was Managing Director of Investment Banking of Dawson James...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$1.29m | 0.45% $ 87.6k | |
| Chief Financial Officer | less than a year | US$431.43k | 0.040% $ 7.8k | |
| Senior Vice President for Clinical Operations | 3.6yrs | no data | no data |
Experienced Management: LNAI's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$1.29m | 0.45% $ 87.6k | |
| Independent Director | 1.1yrs | US$127.16k | 0.052% $ 10.1k | |
| Independent Director | 1.1yrs | US$123.32k | 0.052% $ 10.1k | |
| Member of Respiratory Diseases Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of HBV Scientific Advisory Board | 4.3yrs | no data | no data | |
| Chairperson of HBV Cure Scientific Advisory Board | 5.3yrs | US$129.74k | no data | |
| Member of HBV Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 1.1yrs | US$115.76k | 0.052% $ 10.1k | |
| Chairman of HIV Scientific Advisory Board | 7.3yrs | no data | no data | |
| Member of HIV Scientific Advisory Board | 7.8yrs | no data | no data | |
| Member of HBV Scientific Advisory Board | 5.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 1.6yrs | no data | no data |
Experienced Board: LNAI's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/05 04:48 |
| End of Day Share Price | 2025/11/05 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lunai Bioworks Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.